ECSP088241A - AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME - Google Patents
AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAMEInfo
- Publication number
- ECSP088241A ECSP088241A EC2008008241A ECSP088241A ECSP088241A EC SP088241 A ECSP088241 A EC SP088241A EC 2008008241 A EC2008008241 A EC 2008008241A EC SP088241 A ECSP088241 A EC SP088241A EC SP088241 A ECSP088241 A EC SP088241A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- cytotoxic
- antigen
- specific
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen conjugados citotóxicos que comprenden un agente de enlace celular y un agente citotóxico, composiciones terapéuticas que comprenden el conjugado, métodos para usar los conjugados en la inhibición del crecimiento celular y el tratamiento de la enfermedad, y un equipo que comprende el conjugado citotóxico en todas las modalidades de la invención. En particular, el agente de enlace celular es un anticuerpo monoclonal, y fragmentos de enlace de epítope del mismo, que reconoce y enlaza el glicótopo CA6. La presente invención también está dirigida a versiones humanizadas o recubiertas de DS6, un anticuerpo monoclonal anti-CA6 murino, y fragmentos de enlace de epítope del mismo.Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and treatment of the disease, and a kit comprising the cytotoxic conjugate are described in all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope binding fragments thereof, which recognizes and binds the CA6 glycopepo. The present invention is also directed to humanized or coated versions of DS6, a murine anti-CA6 monoclonal antibody, and epitope binding fragments thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/030115 WO2007024222A1 (en) | 2005-08-22 | 2005-08-22 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088241A true ECSP088241A (en) | 2008-04-28 |
Family
ID=37771883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008241A ECSP088241A (en) | 2005-08-22 | 2008-03-05 | AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1917034A4 (en) |
JP (1) | JP2009504193A (en) |
CN (1) | CN101242855A (en) |
AU (1) | AU2005335743A1 (en) |
BR (1) | BRPI0520509A2 (en) |
CA (1) | CA2615761A1 (en) |
EA (1) | EA020130B9 (en) |
EC (1) | ECSP088241A (en) |
HK (1) | HK1211965A1 (en) |
IL (2) | IL189628A0 (en) |
MX (1) | MX2008002607A (en) |
NO (1) | NO20080893L (en) |
WO (1) | WO2007024222A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
US9844607B2 (en) | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
RU2015137856A (en) * | 2013-02-05 | 2017-03-13 | Санофи | IMMUNOLOGICAL VISUALIZING AGENT FOR USE IN ANTI-MEDICINE CONJUGATE TREATMENT |
WO2014122529A1 (en) * | 2013-02-05 | 2014-08-14 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US20160347856A1 (en) * | 2013-08-02 | 2016-12-01 | Sanofi | Use of Anti-MUC1 Maytansinoid Immunoconjugate Antibody for the Treatment of Solid Tumors |
EP3188761A4 (en) | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Methods for formulating antibody drug conjugate compositions |
CN116514903A (en) | 2014-09-03 | 2023-08-01 | 伊缪诺金公司 | Cytotoxic benzodiazepine derivatives |
US9381256B2 (en) | 2014-09-03 | 2016-07-05 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
RU2765098C2 (en) | 2017-02-28 | 2022-01-25 | Иммуноджен, Инк. | Maitanzinoid derivatives with self-splitting peptide linkers and their conjugates |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
BRPI0410260A (en) * | 2003-05-14 | 2006-05-16 | Immunogen Inc | drug conjugate composition |
BRPI0412879A8 (en) * | 2003-07-21 | 2015-12-15 | Immunogen Inc | CA6 ANTIGEN SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF ITS USE |
-
2005
- 2005-08-22 WO PCT/US2005/030115 patent/WO2007024222A1/en active Application Filing
- 2005-08-22 MX MX2008002607A patent/MX2008002607A/en not_active Application Discontinuation
- 2005-08-22 CA CA002615761A patent/CA2615761A1/en not_active Abandoned
- 2005-08-22 CN CNA200580051368XA patent/CN101242855A/en active Pending
- 2005-08-22 BR BRPI0520509-3A patent/BRPI0520509A2/en not_active Application Discontinuation
- 2005-08-22 JP JP2008527882A patent/JP2009504193A/en not_active Withdrawn
- 2005-08-22 EA EA200800642A patent/EA020130B9/en not_active IP Right Cessation
- 2005-08-22 AU AU2005335743A patent/AU2005335743A1/en not_active Abandoned
- 2005-08-22 EP EP05788869A patent/EP1917034A4/en not_active Withdrawn
-
2008
- 2008-02-20 IL IL189628A patent/IL189628A0/en unknown
- 2008-02-20 NO NO20080893A patent/NO20080893L/en not_active Application Discontinuation
- 2008-03-05 EC EC2008008241A patent/ECSP088241A/en unknown
-
2015
- 2015-05-13 IL IL238798A patent/IL238798A0/en unknown
- 2015-12-31 HK HK15112923.0A patent/HK1211965A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20080893L (en) | 2008-05-22 |
WO2007024222A1 (en) | 2007-03-01 |
AU2005335743A1 (en) | 2007-03-01 |
HK1211965A1 (en) | 2016-06-03 |
CA2615761A1 (en) | 2007-03-01 |
IL238798A0 (en) | 2015-06-30 |
CN101242855A (en) | 2008-08-13 |
BRPI0520509A2 (en) | 2009-05-12 |
EA020130B9 (en) | 2014-10-30 |
EP1917034A1 (en) | 2008-05-07 |
MX2008002607A (en) | 2008-03-19 |
JP2009504193A (en) | 2009-02-05 |
IL189628A0 (en) | 2008-06-05 |
EP1917034A4 (en) | 2009-04-29 |
EA020130B1 (en) | 2014-08-29 |
EA200800642A1 (en) | 2008-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088241A (en) | AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME | |
CR8207A (en) | AN ANCIENT- SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME | |
CY1118369T1 (en) | CATALOGS AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | |
CR10308A (en) | HUMANIZED MONOCLONAL ANTIBODIES FOR THE HEPATOCITE GROWTH FACTOR | |
UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
CY1112277T1 (en) | HUMANIZED ANTI-β7 COMPETITORS AND THEIR USES | |
PE20110668A1 (en) | ANTI-STROMAL THYMIC LYMPHOPOYETIN ANTIBODIES (ANTI-TSLP) | |
AR059809A1 (en) | ANTI-5T4 ANTIBODIES AND THEIR USES | |
CL2008003361A1 (en) | Monoclonal antibodies that bind to hgm-csf and the average compositions that comprise them. | |
AR057807A1 (en) | ANTI-CD3 ANTIBODY FORMULATIONS | |
SG153825A1 (en) | Multivalent immunoglobulin-based bioactive assemblies | |
EA200970923A1 (en) | ANTI-EpSAM ANTIBODY AND ITS APPLICATION | |
DK2109623T3 (en) | Cancer treatment with anti-IL-1 antibodies | |
BR112021025720A2 (en) | Antitissue factor antibody-drug conjugates and related methods | |
AR055072A1 (en) | USE OF ANTI-MADCAM ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE AND TROPICAL ESPRUE | |
CR9823A (en) | AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME | |
CR20140095A (en) | AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME | |
EA202190387A1 (en) | ANTIBODY TO HUMAN CD38 AND ITS USE |